Assessment and management of cutaneous reactions with amifostine administration: Findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP)

International Journal of Radiation Oncology Biology Physics

Volumn 60, Issue 1, 2004, Pages 302-309

  Boccia, Ralph ^a,l   Anné, Pramila Rani ^b   Bourhis, Jean ^c   Brizel, David ^d   Daly, Carrie ^e   Holloway III, Nathaniel ^f   Hymes, Sharon ^g   Koukourakis, Michael ^h   Kozloff, Mark ⁱ   Turner, Maria ^j   Wasserman, Todd ^k  

^a Medical Oncology Branch   (United States)

^b THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e SAINT JOSEPH HOSPITAL   (United States)

^f Jr Hospital of Cook County   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

ⁱ Ingalls Memorial Hospital   (United States)

^j NATIONAL INSTITUTES OF HEALTH   (United States)

^k WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l No 4100 ^*  (United States)

more..

Author keywords

Amifostine; Erythema multiforme; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

CUTANEOUS REACTION; POSTMARKETING; SKIN REACTION;

PATIENT TREATMENT; RADIATION; RADIOTHERAPY; REACTION KINETICS;

SKIN;

AMIFOSTINE; ASPARAGINASE; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; IMATINIB; METHOTREXATE; MITHRAMYCIN; MITOMYCIN C; PACLITAXEL; RADIOPROTECTIVE AGENT; RITUXIMAB; TAMOXIFEN; THALIDOMIDE; TREOSULFAN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLISTER; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; ERYTHEMA MULTIFORME; EVALUATION; FEMALE; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIFOSTINE; BLISTER; CHILD; CHILD, PRESCHOOL; DRUG ERUPTIONS; EPIDERMAL NECROLYSIS, TOXIC; ERYTHEMA MULTIFORME; HUMANS; INCIDENCE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RADIATION-PROTECTIVE AGENTS; STEVENS-JOHNSON SYNDROME;

EID: 4444367495     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2004.02.026     Document Type: Article

References (47)

1. Zlotolow I.M. Dental oncology and maxillofacial prosthetics. Harrison L.B., Sessions R.B., Hong W.K. Head and neck cancer: A multidisciplinary approach. 1999;151-168 Lippincott Raven, Philadelphia
2. Ethyol (amifostine) prescribing information. Gaithersburg, MD: MedImmune Oncology, Inc.; 2001
3. Antonadou D., Pepelassi M., Synodinou M., et al. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 52:2002;739-747
4. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 18:2000;3339-3345
5. Buntzel J., Kuttner K., Frohlich D., et al. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 9:1998;505-509
6. Hensley M.L., Schuchter L.M., Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 17:1999;3333-3355
7. Schuchter L.M., Hensley M.L., Meropol N.J., et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 20:2002;2895-2903
8. Koukourakis M.I., Kyrias G., Kakolyris S., et al. Subcutaneous administration of amifostine during fractionated radiotherapy A randomized phase II study. J Clin Oncol. 18:2000;2226-2233
9. Anne P.R. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol. 29:2002;80-83
10. Rzany B., Mockenhaupt M., Baur S., et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992) Structure and results of a population-based registry. J Clin Epidemiol. 49:1996;769-773
11. Roujeau J.C., Kelly J.P., Naldi L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 333:1995;1600-1607
12. Rzany B., Correia O., Kelly J.P., et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy A case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet. 353:1999;2190-2194
13. deShazo R.D., Kemp S.F. Allergic reactions to drugs and biologic agents. JAMA. 278:1997;1895-1906
14. Roujeau J.C., Stern R.S. Severe adverse cutaneous reactions to drugs. N Engl J Med. 331:1994;1272-1285
15. Meunier P., Castaigne S., Bastie J.N., et al. Cutaneous reactions after treatment with 2-chlorodeoxyadenosine. Acta Derm Venereol. 76:1996;385-386
16. Grey M.R., Flanagan N.G., Kelsey P.R. Severe skin rash in two consecutive patients treated with 2-chlorodeoxyadenosine for hairy cell leukaemia at a single institution. Clin Lab Haematol. 22:2000;111-113
17. Talamonti M.S., Catalano P.J., Vaughn D.J., et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer A regimen with unexpected early toxicity. J Clin Oncol. 18:2000;3384-3389
18. Lo S.K., Yip D., Leslie M., et al. 5-fluorouracil-induced erythema multiforme. Int J Clin Pract. 53:1999;219-221
19. Brodsky A., Aparici I., Argeri C., et al. Stevens-Johnson syndrome, respiratory distress and acute renal failure due to synergic bleomycin-cisplatin toxicity. J Clin Pharmacol. 29:1989;821-823
20. Giaccone G., Risio M., Bonardi G., et al. Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin A case report. Tumori. 72:1986;331-333
21. Ozkan A., Apak H., Celkan T., et al. Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside. Pediatr Dermatol. 18:2001;38-40
22. Stasi R., Gatti S., Perrotti A., et al. Erythema multiforme during GM-CSF therapy. Acta Derm Venereol. 74:1994;132-134
23. Rodriguez A.R. L-asparaginase and toxic epidermal necrolysis. J Med Assoc Ga. 69:1980;355-357
24. Newman J.M., Rindler J.M., Bergfeld W.F., et al. Stevens-Johnson syndrome associated with topical nitrogen mustard therapy. J Am Acad Dermatol. 36:1997;112-114
25. Brauer M.J., McEvoy B.F., Mitus W.J. Hypersensitivity to nitrogen mustards in the form of erythema multiforme. A unique adverse reaction. Arch Intern Med. 120:1967;499-503
26. Purpora D., Ahern M.J., Silverman N. Toxic epidermal necrolysis after mithramycin. N Engl J Med. 299:1978;1412
27. Spencer H.J. Local erythema multiforme-like drug reaction following intravenous mitomycin C and 5-fluorouracil. J Surg Oncol. 26:1984;47-50
28. Hsiao L.T., Chung H.M., Lin J.T., et al. Stevens-Johnson syndrome after treatment with STI571 A case report. Br J Haematol. 117:2002;620-622
29. Scheulen M.E., Hilger R.A., Oberhoff C., et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res. 6:2000;4209-4216
30. Arias D., Requena L., Hasson A., et al. Localized epidermal necrolysis (erythema multiforme-like reaction) following intravenous injection of vinblastine. J Cutan Pathol. 18:1991;344-346
31. Mulder K.E., Severin D., Tonkin K., et al. Docetaxel-associated radiation recall dermatitis. Curr Oncol. 9:2002;48-51
32. Solberg L.A. Jr, Wick M.R., Bruckman J.E. Doxorubicin-enhanced skin reaction after whole-body electron-beam irradiation for leukemia cutis. Mayo Clin Proc. 55:1980;711-715
33. Miller D.L., Balter S., Noonan P.T., et al. Minimizing radiation-induced skin injury in interventional radiology procedures. Radiology. 225:2002;329-336
34. Veness M.J., Dwyer P.K. Erythema multiforme-like reaction associated with radiotherapy. Australas Radiol. 40:1996;334-337
35. Ridgway H.B., Miech D.J. Erythema multiforme (Stevens-Johnson syndrome) following deep radiation therapy. Cutis. 51:1993;463-464
36. Howell W.R., Knight A.L., Scruggs H.J. Stevens-Johnson syndrome after radiotherapy. South Med J. 83:1990;681-683
37. Inachi S., Mizutani H., Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol. 133:1997;845-849
38. Paul C., Wolkenstein P., Adle H., et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 134:1996;710-714
39. Dewey W.C., Ling C.C., Meyn R.E. Radiation-induced apoptosis Relevance to radiotherapy. Int J Radiat Oncol Biol Phys. 33:1995;781-796
40. Duncan K.O., Tigelaar R.E., Bolognia J.L. Stevens-Johnson syndrome limited to multiple sites of radiation therapy in a patient receiving phenobarbital. J Am Acad Dermatol. 40:1999;493-496
41. Roujeau J.C. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol. 24:1997;726-729
42. Knowles S.R., Uetrecht J., Shear N.H. Idiosyncratic drug reactions The reactive metabolite syndromes. Lancet. 356:2000;1587-1591
43. Bastuji-Garin S., Rzany B., Stern R.S., et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 129:1993;92-96
44. Cote B., Wechsler J., Bastuji-Garin S., et al. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol. 131:1995;1268-1272
45. Roujeau J.C., Guillaume J.C., Fabre J.P., et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981-1985. Arch Dermatol. 126:1990;37-42
46. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 282:1998;490-493
47. Frangogiannis N.G., Boridy I., Mazhar M., et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J. 89:1996;1001-1003